303 related articles for article (PubMed ID: 26611471)
1. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
[No Abstract] [Full Text] [Related]
2. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH
Nat Commun; 2019 Apr; 10(1):1911. PubMed ID: 31015454
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
Szabo AG; Gang AO; Pedersen MØ; Poulsen TS; Klausen TW; Nørgaard P
Leuk Lymphoma; 2016 Nov; 57(11):2526-34. PubMed ID: 27243588
[TBL] [Abstract][Full Text] [Related]
4. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC; Doughty C; Dahir NB; Begum DB; Young K; Walker BA; Hoffmann P; Nöthen MM; Davies FE; Klein B; Goldschmidt H; Morgan GJ; Houlston RS; Hose D; Hemminki K
Haematologica; 2015 Mar; 100(3):e110-3. PubMed ID: 25480495
[No Abstract] [Full Text] [Related]
5. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
6. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
7. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
[TBL] [Abstract][Full Text] [Related]
8. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
9. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
[No Abstract] [Full Text] [Related]
10. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
11. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
12. A novel human multiple myeloma-derived cell line, NCU-MM-1, carrying t(2;11)(q11;q23) and t(8;22)(q24;q11) chromosomal translocations with overexpression of c-Myc protein.
Iida S; Hanamura I; Suzuki T; Kamiya T; Kato M; Hayami Y; Miura K; Harada S; Tsuboi K; Wakita A; Akano Y; Taniwaki M; Nitta M; Ueda R
Int J Hematol; 2000 Jul; 72(1):85-91. PubMed ID: 10979215
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M; Steurer M; Jukic E; Keller MA; Fresser F; Ruepp C; Wöll E; Verdorfer I; Gastl G; Willenbacher W; Weger R; Nachbaur D; Wolf D; Gunsilius E; Zschocke J; Steiner N
Am J Hematol; 2020 Dec; 95(12):1562-1571. PubMed ID: 32936982
[TBL] [Abstract][Full Text] [Related]
14. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
15. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Chesi M; Bergsagel PL
Int J Hematol; 2013 Mar; 97(3):313-23. PubMed ID: 23456262
[TBL] [Abstract][Full Text] [Related]
17. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
19. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
[TBL] [Abstract][Full Text] [Related]
20. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
